From Raquel de Oliveira Martins, HAE Brazil (Abranghe)
Public hearing about HAE: HAE Brazil, Abranghe, was invited to participate in the public hearing at the Health Committee of the Chamber of Deputies on 16 May 2023 to debate access to treatment for hereditary angioedema.
At the Health Commission hearing, experts and diagnosed patients explained details about the disease. The date of 16 May was chosen for the debate as it is hae day :-) – the international awareness day for hae.
HAE Brazil has existed since 2010 with the main objective of demonstrating that HAE patients are not alone.
>> Watch the hearing on the Chamber of Deputies YouTube channel
>> Read more on the Chamber of Deputies website here and here
Access to new treatments: CONITEC (the body responsible for recommending the incorporation of the medicine into the list of the Basic Health System (SUS) has recommended the incorporation of intravenous C1 esterase inhibitor (Berinert) and icatibant (Firazyr) for the treatment of HAE attacks, meaning that patients will have both medicines available from the government.
Brazilian Allergy and Immunology Congress took place in Maceió from 17-20 November. HAE Brazil participated, handed out leaflets to doctors, and registered 12 new doctors for the medical network.
New drug approval: The Collegiate Board of the National Supplementary Health Agency (ANS) approved the incorporation of the drug lanadelumab into the List of Mandatory Procedures. The medicine is indicated for long-term prevention in patients with hereditary angioedema (HAE) from the age of 12.
The proposal to incorporate the technology was submitted directly to the ANS, having gone through the Agency’s evaluation processes, including broad social participation and careful technical analysis, which uses the Health Technology Assessment (ATS) methodology, similar to countries such as England, Canada, Australia, and Germany.
Lanadelumab will have mandatory coverage with the update of the Normative Resolution from 2 October, when it will be included in the List, in accordance with its usage guidelines.
